BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
نویسندگان
چکیده
منابع مشابه
MYELOID NEOPLASIA BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
1Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; 2School of Medicine, University of Adelaide, Adelaide, Australia; 3Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia; 4Molecular Genetics Research Institute, Catholic University of Korea, Seoul, South Korea; and 5Department of Haematology and Genet...
متن کاملBCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
Rising BCR-ABL1 transcripts indicate potential loss of imatinib response in CML. We determined whether the BCR-ABL1 doubling time could distinguish nonadherence from resistance as the cause of lost response. Distinct groups were examined: (1) acquired clinical resistance because of blast crisis and/or BCR-ABL1 mutations; and (2) documented imatinib discontinuation/interruption. Short doubling t...
متن کاملVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse events (VAEs) have been described in patients receiving second- or third-generation BCR/ABL1 TKIs....
متن کاملBlood Spotlight Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors
Vienna, Austria; Department/Clinic for Companion Animals and Horses, Clinic for Small Animals, Clinical Unit of Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria; Medical Clinic III for Oncology, Haematology and Rheumatology, University Hospital Bonn (UKB), Bonn, ...
متن کاملInterferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients
Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We used an alternative treatment strategy with interferon-α (IFN-α) given solo, sequentially or tog...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2019
ISSN: 2234-943X
DOI: 10.3389/fonc.2019.00764